On January 15, Baxter laid off about 100 people in the care communications division which focuses on nurse call, RTS, and wireless phones
6 replies (most recent on top)
Layoffs hit the C-suite and senior leadership hard. Long overdue!
Baxter cut senior leadership last week -- e.g. Jerry Greco -- but have avoided making it public and are still listing several of the "out of work" execs on their website. Shame on them!
Bax did a HUGE MISTAKE when they bought a close to bankruptcy HILLROM company that make a myriad of small cheap products that require tons of efforts to keep them aligned with internal quality and FDA requirements. In addition they did not invest in R&D to develop new products and sold the money maker Renal division. One mistake after another, that punishes investors only since the CEO and BOD got in full their money, no matter how low Bax was going.
@dw GPTZero says there is a 100% chance your post was written by an AI. Why would you post that AI slop here? If you have information or an actual fu--ing take, post it. If you're just going to give head to a clanker and post its ji-z here, GTFO.
Baxter is expected to announce a new round of layoffs next week. This initial phase is anticipated to impact senior leadership and several key commercial functions, including the Pharmaceutical General Manager role, members of the Marketing organization, the IDN Contracting team, and other positions across the company. This is understood to be the first phase of a broader restructuring effort, with additional rounds possible.
The newly appointed CEO and leadership team appear to have a defined restructuring strategy in place, driven by the company’s ongoing financial challenges. There is increasing recognition within the organization that the Hill-Rom acquisition was significantly overvalued and has contributed meaningfully to Baxter’s current financial and operational constraints.
Commercial execution has also been a persistent challenge. Sales quotas have frequently been misaligned with both market conditions and product availability, placing undue pressure on the field and undermining performance credibility. These challenges have been exacerbated by repeated supply disruptions across Baxter’s pharmaceutical portfolio, particularly within the frozen premix category, which has historically been a core strength.
At the same time, competitive dynamics continue to intensify. Competitors are advancing room-temperature pharmaceutical alternatives that directly challenge Baxter’s frozen premix offerings, eroding differentiation and market share. As a result, Baxter’s pharmaceutical portfolio is increasingly perceived as lagging behind competitor innovation and market responsiveness.
Collectively, these factors underscore a broader organizational reset focused on financial stabilization, operational discipline, and structural realignment in response to evolving market realities.
Baxter is a trailing edge failure. They are trying (for example) to copy the Vocera tech that Stryker acquired. Their offering will not be ready for market in the foreseeable future. Everything they sell is a commodity.